SAN DIEGO--(BUSINESS WIRE)--Novocell, Inc., a stem cell engineering company, today announced that it has received U.S. Patent No. 7,541,185 with method claims covering the use of endoderm cells derived from human embryonic stem cells (hESCs) for drug discovery. This is the second U.S. patent issued to Novocell related to human endoderm. U.S. Patent No. 7,510,876, issued on March 31, 2009, is directed to an in vitro human endoderm composition.
